(Q24792780)

English

Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759] (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

0 references

Markus Büchler

15

object named as

M W Büchler

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

author name string

H P Knaebel

1

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

A Märten

2

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

J Schmidt

3

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

K Hoffmann

4

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

C Seiler

5

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

K Lindel

6

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

H Schmitz-Winnenthal

7

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

S Fritz

8

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

T Herrmann

9

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

H Goldschmidt

10

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

R Krempien

11

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

U Mansmann

12

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

V Diehl

14

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

language of work or name

0 references

publication date

12 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

1

0 references

37

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Mechanisms of Interferon-alpha induced apoptosis in malignant cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

7 April 2017

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1186/1471-2407-5-37

22 April 2017

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

7 April 2017

The Virginia Mason approach to localized pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

Immunotherapy of metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

Cancer immunotherapy: the interferon-alpha experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

The biological treatment of renal-cell carcinoma and melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

How does interferon-alpha exert its antitumour activity in multiple myeloma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

28 September 2017

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

30 May 2018

Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1087479

30 May 2018

Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-37

21 January 2018

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-37

21 January 2018

Practical Bayesian guidelines for phase IIB clinical trials.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-37

21 January 2018

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-37

21 January 2018

Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-5-37

21 January 2018

Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant interferon-alpha improves skin cancer survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15826316

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-5-37

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Dimensions Publication ID

0 references

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24792780&oldid=2176862129"